- Company
- RRMS, actively expanding coverage of drugs
- by Eo, Yun-Ho Feb 16, 2021 06:07am
- There is news of expanding coverage of oral RRMS (Relapsing-remitting multiple sclerosis) drugs. According to industry sources on the 8th, after Mavenclad (Cladribine, Merck) was listed in insurance benefits in the second half of last year, Sanofi Genzyme's primary drug Aubagio was expanded from February. In the case of Aubagio, additio
- Policy
- The redemption of α-GPC benefits extended until March 15
- by Lee, Hye-Kyung Feb 15, 2021 06:17am
- The contract for reimbursement of benefits related to α-GPC, a brain function improvement drug, was extended until March 15th. The MOHW ordered The NHIS to extend the deadline for negotiations on the Choline alfoscerate formulation on the 10th. February 10, which ordered an extension of the negotiation period, marks the end of the first negotia
- Policy
- NHIS refuses to disclose immunotherapy reevaluation result
- by Moon, sung-ho Feb 15, 2021 06:16am
- Although the National Health Insurance Service (NHIS) has conducted a reevaluation on immunotherapies listed for reimbursement, the government agency decided to keep the outcome undisclosed. On the contrary, the Health Insurance Review and Assessment Service (HIRA) disclosed the outcome of a consignment research done with the same topic. The
- Policy
- Janssen, to close Hyangnam plant in Korea
- by Lee, Tak-Sun Feb 15, 2021 06:16am
- With the withdrawal of the Hyangnam factory this year, Janssen Korea is reorganizing its domestic product lineup of Tylenol and Ultracet The production of Tylenol 8 hours ER and Ultracet is undergoing a transition or shutdown procedure. According to the MFDS on the 8th, all Ultracet products, an analgesic combination drug containing Tra
- Policy
- Drug exempt from economic evaluation,cut to the lowest price
- by Lee, Hye-Kyung Feb 15, 2021 06:16am
- The NHIS continues to monitor foreign drug prices after signing and listing a drug price reduction contract linked to foreign prices for drugs exempt from economic evaluation in accordance with the drug price negotiation guidelines. In the past three years from 2018 to 2020, after 30 items of 14 pharmaceutical companies were listed on the lis
- Policy
- AstraZeneca vaccine authorized for use in Korea on Feb. 10
- by Lee, Tak-Sun Feb 15, 2021 06:16am
- The COVID-19 vaccine developed by AstraZeneca was finally approved by the South Korean health authority on Feb. 10. The approval is valid for the age group over 18, including elders older than 65. On Feb. 10, South Korea’s Ministry of Food and Drug Safety (MFDS) convened a Final Inspection Committee to make a decision on authorizing Ast
- Company
- Generics for Xeljanz are being approved one after another
- by Kim, Jin-Gu Feb 10, 2021 06:05am
- Generics for Xeljanz (Tofacitinib) are being approved one after another. After crystalline form patent was deleted from the list, it seems that domestic companies are competitively receiving generic licenses. According to the MFDS on the 9th, until this day, a total of 42 generics for Xeljanz have been licensed. Since Boryung's generic wa
- Company
- Despite COVID-19 and NDMA metformin prescription surges
- by Chon, Seung-Hyun Feb 10, 2021 06:04am
- Metformin-based antidiabetic drugs showed exceptional growth in the prescription drug market. Both metformin combination and single agent drugs expanded their prescription volume and maintained the credibility in the clinical scene, regardless of the novel coronavirus disease (COVID-19) outbreak and impurity contamination incident. On Feb. 9
- Company
- More options for ankylosing spondylitis including Taltz
- by Feb 9, 2021 06:04am
- The interleukin 17A (IL-17A) inhibitor drugs are taking over the spotlight in the ankylosing spondylitis treatment market. Besides the first-in-class Cosentyx (secukinumab), Taltz (ixekizumab) was released to the South Korean market with its strong evidences. Some specialists predict the guideline, initially recommending the drug to be used
- Policy
- On-site judgment is important
- by Lee, Tak-Sun Feb 9, 2021 06:04am
- COVID-19 vaccine by AZ, along with CMA, recommended that those over 65 years of age should review it by the Vaccination Specialist Committee, the Central Pharmaceutical Affairs Review Committee of the MFDS said it was because on-site judgment was important. In a briefing held on the 5th, Chairman Il-Hwan Oh said, "Because the data on the
